peptide drug conjugate | Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

41,233 results for “peptide drug conjugate”

Trials

View all 15406 →

Peptide-drug-conjugates for Personalized, Targeted Therapy of Chronic Lymphocytic Leukemia

30 participants · First posted Jul 12, 2016

Not yet recruiting

A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors

74 participants · First posted Sep 10, 2026

Not yet recruiting

Protein-Matched ADC or PDC Umbrella Trial in Advanced Pancreatic and Breast Cancer

225 participants · First posted Sep 17, 2026

Drugs

View all 2256 →

OTS-P19

Investigational

Nendratareotide uzatansine

antibody-drug conjugate 3

Organizations

View all 268 →

PeptiDream

Japan

Redpharm Drug

United States

Chain Drug Consortium

United States

News

View all 23303 →

Avacta Develops First Dual-Payload Peptide Drug Conjugate Platform for Cancer Combination Therapy

TwoStep Therapeutics Raises $62.5M Series A and Wins FDA IND Clearance for First-in-Class Multi-Specific Peptide-Drug Conjugate TS-104

Peptide Drug Conjugates Emerge as Next-Generation Cancer Therapeutics with Over 30 Candidates in Clinical Development

Page 1 of 4124